Crispr Therapeutics AG (CRSP) — Cash Flow Quality Index
Crispr Therapeutics AG (CRSP) has a Cash Flow Quality Index of -1.08x as of December 2023. Operating cash flow of $-96.07 Million is below net income of $89.35 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how much of Crispr Therapeutics AG's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Crispr Therapeutics AG Cash Flow Quality Index (2019–2021)
Historical Cash Flow Quality Index for Crispr Therapeutics AG across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Crispr Therapeutics AG (CRSP) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Crispr Therapeutics AG (2019–2021)
Year-by-year earnings quality comparison for Crispr Therapeutics AG. For live market cap and the full company financial profile, see Crispr Therapeutics AG stock valuation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 1.43x | $538.97 Million | $377.66 Million | ▲ +68.3% |
| 2019 | 0.85x | $56.68 Million | $66.86 Million | — |